Literature DB >> 31562770

Examining the Use of Real-World Evidence in the Regulatory Process.

Brett K Beaulieu-Jones1, Samuel G Finlayson1, William Yuan1, Russ B Altman2, Isaac S Kohane1, Vinay Prasad3, Kun-Hsing Yu1.   

Abstract

The 21st Century Cures Act passed by the United States Congress mandates the US Food and Drug Administration to develop guidance to evaluate the use of real-world evidence (RWE) to support the regulatory process. RWE has generated important medical discoveries, especially in areas where traditional clinical trials would be unethical or infeasible. However, RWE suffers from several issues that hinder its ability to provide proof of treatment efficacy at a level comparable to randomized controlled trials. In this review article, we summarized the advantages and limitations of RWE, identified the key opportunities for RWE, and pointed the way forward to maximize the potential of RWE for regulatory purposes.
© 2019 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Year:  2019        PMID: 31562770     DOI: 10.1002/cpt.1658

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

1.  Natural language inference for curation of structured clinical registries from unstructured text.

Authors:  Bethany Percha; Kereeti Pisapati; Cynthia Gao; Hank Schmidt
Journal:  J Am Med Inform Assoc       Date:  2021-12-28       Impact factor: 4.497

Review 2.  Leveraging external data in the design and analysis of clinical trials in neuro-oncology.

Authors:  Rifaquat Rahman; Steffen Ventz; Jon McDunn; Bill Louv; Irmarie Reyes-Rivera; Mei-Yin C Polley; Fahar Merchant; Lauren E Abrey; Joshua E Allen; Laura K Aguilar; Estuardo Aguilar-Cordova; David Arons; Kirk Tanner; Stephen Bagley; Mustafa Khasraw; Timothy Cloughesy; Patrick Y Wen; Brian M Alexander; Lorenzo Trippa
Journal:  Lancet Oncol       Date:  2021-10       Impact factor: 41.316

3.  Temporal Trends in Clinical Evidence of 5-Year Survival Within Electronic Health Records Among Patients With Early-Stage Colon Cancer Managed With Laparoscopy-Assisted Colectomy vs Open Colectomy.

Authors:  Jue Hou; Rachel Zhao; Tianrun Cai; Brett Beaulieu-Jones; Thany Seyok; Kumar Dahal; Qianyu Yuan; Xin Xiong; Clara-Lea Bonzel; Claire Fox; David C Christiani; Thomas Jemielita; Katherine P Liao; Kai-Li Liaw; Tianxi Cai
Journal:  JAMA Netw Open       Date:  2022-06-01

4.  Using observational study data as an external control group for a clinical trial: an empirical comparison of methods to account for longitudinal missing data.

Authors:  Vibeke Norvang; Espen A Haavardsholm; Sara K Tedeschi; Houchen Lyu; Joseph Sexton; Maria D Mjaavatten; Tore K Kvien; Daniel H Solomon; Kazuki Yoshida
Journal:  BMC Med Res Methodol       Date:  2022-05-28       Impact factor: 4.612

5.  Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019.

Authors:  Sini Marika Eskola; Hubertus Gerardus Maria Leufkens; Andrew Bate; Marie Louise De Bruin; Helga Gardarsdottir
Journal:  Clin Pharmacol Ther       Date:  2021-11-16       Impact factor: 6.903

6.  Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness?

Authors:  Jim Slattery; Xavier Kurz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-04-16       Impact factor: 2.890

Review 7.  Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development.

Authors:  Timothy A Yap; Ira Jacobs; Elodie Baumfeld Andre; Lauren J Lee; Darrin Beaupre; Laurent Azoulay
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

8.  Preventive effect of rebamipide on NSAID-induced lower gastrointestinal tract injury using FAERS and JADER.

Authors:  Toru Imai; Katsuyuki Hazama; Yasuhiro Kosuge; Shinichiro Suzuki; Susumu Ootsuka
Journal:  Sci Rep       Date:  2022-02-16       Impact factor: 4.379

9.  What is ahead for health policy and technology in the 2020s?

Authors:  Donald R J Singer; Ken Redekop
Journal:  Health Policy Technol       Date:  2020-02-05

10.  Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.

Authors:  Wei Fang Dai; Claire de Oliveira; Scott Blommaert; Reka E Pataky; David Tran; Zeb Aurangzeb; Cynthia Kendell; Chris Folkins; Chandy Somayaji; Jeff Dowden; Winson Cheung; Erin Strumpf; Jaclyn M Beca; Carol McClure; Robin Urquhart; James Ted McDonald; Riaz Alvi; Donna Turner; Stuart Peacock; Avram Denburg; Rebecca E Mercer; Caroline Muñoz; Ambica Parmar; Mina Tadrous; Pam Takhar; Kelvin K W Chan
Journal:  Curr Oncol       Date:  2022-03-17       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.